Fiera Capital Corp Has $23.89 Million Stock Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Fiera Capital Corp raised its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 3.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 805,150 shares of the company's stock after purchasing an additional 25,186 shares during the quarter. Fiera Capital Corp owned 1.61% of Immunocore worth $23,889,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in Immunocore during the 4th quarter valued at approximately $25,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Immunocore in the 1st quarter worth approximately $225,000. NEOS Investment Management LLC boosted its position in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the period. Tema Etfs LLC acquired a new position in Immunocore during the 4th quarter valued at approximately $330,000. Finally, Virtus ETF Advisers LLC boosted its position in Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Down 2.2%

Shares of IMCR traded down $0.73 during trading hours on Thursday, hitting $32.77. 267,182 shares of the company were exchanged, compared to its average volume of 238,892. The firm's 50 day moving average is $34.19 and its 200-day moving average is $31.09. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $40.52. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.31 and a current ratio of 6.36.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same quarter in the previous year, the firm earned ($0.49) EPS. The firm's revenue was up 33.6% compared to the same quarter last year. As a group, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IMCR shares. Mizuho reduced their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft started coverage on Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $71.00 price target on shares of Immunocore in a research report on Thursday, April 10th. Finally, Oppenheimer upped their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.